Changchun BCHT Biotechnology Co. (SHA:688276)
China
· Delayed Price · Currency is CNY 20.76
-0.35 (-1.66%)
May 22, 2025, 2:45 PM CST
SHA:688276 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2018 - 2019 |
| Operating Revenue | 1,229 | 1,825 | 1,071 | 1,201 | 1,440 | Upgrade
|
| Other Revenue | - | 0.14 | 0.05 | 0.75 | 1.36 | Upgrade
|
| Revenue | 1,229 | 1,825 | 1,071 | 1,202 | 1,441 | Upgrade
|
| Revenue Growth (YoY) | -32.64% | 70.30% | -10.86% | -16.61% | 47.73% | Upgrade
|
| Cost of Revenue | 179.18 | 210.35 | 181.93 | 228.56 | 176.27 | Upgrade
|
| Gross Profit | 1,050 | 1,614 | 889.52 | 973.47 | 1,265 | Upgrade
|
| Selling, General & Admin | 587.89 | 800.93 | 552.73 | 555.93 | 689.48 | Upgrade
|
| Research & Development | 156.14 | 198.07 | 133.53 | 156.76 | 93.36 | Upgrade
|
| Other Operating Expenses | 5.16 | 13.04 | 9.7 | 10.58 | 10.67 | Upgrade
|
| Operating Expenses | 749.2 | 1,072 | 729.59 | 734.04 | 792.91 | Upgrade
|
| Operating Income | 300.71 | 541.96 | 159.93 | 239.43 | 472.18 | Upgrade
|
| Interest Expense | - | -0.7 | - | -0.33 | -4.05 | Upgrade
|
| Interest & Investment Income | - | 12.44 | 18.4 | 11.78 | 7.34 | Upgrade
|
| Earnings From Equity Investments | -0.44 | 0.69 | 0.31 | -1.02 | - | Upgrade
|
| Currency Exchange Gain (Loss) | - | 0.67 | 1.86 | -0.14 | -0.22 | Upgrade
|
| Other Non Operating Income (Expenses) | -4.55 | -0.21 | -0.15 | -0.16 | -0.16 | Upgrade
|
| EBT Excluding Unusual Items | 295.72 | 554.85 | 180.35 | 249.55 | 475.09 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0 | -0.9 | -0.73 | -2.19 | - | Upgrade
|
| Asset Writedown | -39.95 | - | - | - | -0.05 | Upgrade
|
| Other Unusual Items | - | 2.91 | 18.07 | 14.2 | 11.61 | Upgrade
|
| Pretax Income | 255.77 | 563.76 | 197.69 | 261.57 | 486.65 | Upgrade
|
| Income Tax Expense | 23.68 | 62.75 | 16.16 | 18.01 | 68.42 | Upgrade
|
| Net Income | 232.09 | 501.01 | 181.54 | 243.55 | 418.23 | Upgrade
|
| Net Income to Common | 232.09 | 501.01 | 181.54 | 243.55 | 418.23 | Upgrade
|
| Net Income Growth | -53.67% | 175.98% | -25.46% | -41.77% | 89.23% | Upgrade
|
| Shares Outstanding (Basic) | 414 | 414 | 413 | 393 | 367 | Upgrade
|
| Shares Outstanding (Diluted) | 414 | 414 | 413 | 393 | 367 | Upgrade
|
| Shares Change (YoY) | 0.10% | 0.36% | 5.03% | 7.07% | 1.25% | Upgrade
|
| EPS (Basic) | 0.56 | 1.21 | 0.44 | 0.62 | 1.14 | Upgrade
|
| EPS (Diluted) | 0.56 | 1.21 | 0.44 | 0.62 | 1.14 | Upgrade
|
| EPS Growth | -53.72% | 175.00% | -29.03% | -45.61% | 86.89% | Upgrade
|
| Free Cash Flow | -135.92 | -215.46 | -250.91 | -492.58 | -126.58 | Upgrade
|
| Free Cash Flow Per Share | -0.33 | -0.52 | -0.61 | -1.25 | -0.34 | Upgrade
|
| Dividend Per Share | - | 0.150 | 0.150 | 0.100 | - | Upgrade
|
| Dividend Growth | - | - | 50.00% | - | - | Upgrade
|
| Gross Margin | 85.42% | 88.47% | 83.02% | 80.98% | 87.77% | Upgrade
|
| Operating Margin | 24.47% | 29.70% | 14.93% | 19.92% | 32.76% | Upgrade
|
| Profit Margin | 18.88% | 27.46% | 16.94% | 20.26% | 29.02% | Upgrade
|
| Free Cash Flow Margin | -11.06% | -11.81% | -23.42% | -40.98% | -8.78% | Upgrade
|
| EBITDA | 404.89 | 633.94 | 230.87 | 307.76 | 531.04 | Upgrade
|
| EBITDA Margin | 32.94% | 34.74% | 21.55% | 25.60% | 36.84% | Upgrade
|
| D&A For EBITDA | 104.18 | 91.99 | 70.94 | 68.34 | 58.86 | Upgrade
|
| EBIT | 300.71 | 541.96 | 159.93 | 239.43 | 472.18 | Upgrade
|
| EBIT Margin | 24.47% | 29.70% | 14.93% | 19.92% | 32.76% | Upgrade
|
| Effective Tax Rate | 9.26% | 11.13% | 8.17% | 6.89% | 14.06% | Upgrade
|
| Revenue as Reported | - | 1,825 | 1,071 | 1,202 | 1,441 | Upgrade
|
| Advertising Expenses | - | 568.76 | 371.28 | 411.83 | 540.22 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.